Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP1 | P03956 | 1/20 | 0.44 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | PPARA | Q07869 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | MMP9 | P14780 | 1/20 | 0.40 |
| ▸ | MMP8 | P22894 | 1/20 | 0.40 |
| ▸ | CTSS | P25774 | 8/20 | 0.40 |
| ▸ | CTSK | P43235 | 6/20 | 0.40 |
| ▸ | CTSB | P07858 | 3/20 | 0.40 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.40 |
| ▸ | CTSL | P07711 | 2/20 | 0.39 |
| ▸ | PPARG | P37231 | 1/20 | 0.39 |
| ▸ | ATM | Q13315 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30775633 | 1.00 | MMP1 (0.44) | MMP1CA2PPARAMEN1KMT2A | |
| SCHEMBL29979074 | 0.89 | CTSS (0.52) | MMP1CA2PPARAMEN1KMT2A | |
| SCHEMBL10708283 | 0.89 | MMP1 (0.54) | MMP1PPARAMEN1KMT2AMMP9 | |
| SCHEMBL5556795 | 0.89 | MMP1 (0.54) | MMP1PPARAMEN1KMT2AMMP9 | |
| SCHEMBL24815316 | 0.89 | MMP1 (0.54) | MMP1PPARAMEN1KMT2AMMP9 | |
| SCHEMBL24815317 | 0.89 | MMP1 (0.54) | MMP1PPARAMEN1KMT2AMMP9 | |
| SCHEMBL27258420 | 0.85 | MMP1 (0.47) | MMP1MMP9MMP8 | |
| SCHEMBL29979566 | 0.82 | AAK1 (0.42) | MMP1CA2PPARAMEN1KMT2A | |
| SCHEMBL29979124 | 0.82 | CTSS (0.48) | MMP1CA2PPARAMEN1KMT2A | |
| SCHEMBL29980182 | 0.78 | CTSS (0.53) | PPARAMMP9MMP8CTSSCTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12065445-B2 | CDK2 inhibitors and methods of using the same | CEDILLA THERAPEUTICS, INC. (US) | 2024-08-20 | — | — | US | disclosed |
| US-20240174680-A1 | CDK2 INHIBITORS AND METHODS OF USING THE SAME | CEDILLA THERAPEUTICS, INC. (US) | 2024-05-30 | — | — | US | disclosed |
| EP-4284365-A1 | CDK2 INHIBITORS AND METHODS OF USING THE SAME | Cedilla Therapeutics, Inc. (US) | 2023-12-06 | — | — | EP | disclosed |
| US-20230109076-A1 | CDK2 INHIBITORS AND METHODS OF USING THE SAME | CEDILLA THERAPEUTICS, INC. | 2023-04-06 | — | — | US | disclosed |
| WO-2022165513-A1 | CDK2 INHIBITORS AND METHODS OF USING THE SAME | CEDILLA THERAPEUTICS, INC. (US) | 2022-08-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240174680-A1 | CDK2 INHIBITORS AND METHODS OF USING THE SAME | CDK2, CDK20, CDK2AP2 | MMP1 4041/4885CA2 3554/4885PPARA 3679/4885 |
| US-20230109076-A1 | CDK2 INHIBITORS AND METHODS OF USING THE SAME | CDK2, CDK20, CDK2AP2 | MMP1 4041/4885CA2 3554/4885PPARA 3679/4885 |
| US-12065445-B2 | CDK2 inhibitors and methods of using the same | CDK2, CDK20, CDK1 | MMP1 3414/4885CA2 1979/4885PPARA 3800/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.